We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to ...

The researchers received a $3.27 million, five-year grant from the National Cancer Institute to further explore the therapeutic use of vaccines in preclinical models of PDAC.

Background: OSE2101 (TEDOPI) is a therapeutic cancer vaccine composed of multiple peptides restricted to HLA-A2 phenotype targeting tumor-associated antigens (CEA, HER-2, MAGE-2, MAGE-3, P53) ...

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

PharmaJet® Presents Partner Data Demonstrating that Needle-free Delivery Boosts Immune Response of DNA and Novel Therapeutic Cancer Vaccines Provided by Business Wire Apr 17, 2025, 7:05:00 AM ...

Key Takeaways PGV001 vaccine showed strong immune response and was well tolerated in a phase 1 trial with 13 patients across multiple cancer types. At five-year follow-up, six patients were alive, ...

EVM14 is an off-the-shelf mRNA mRNA cancer vaccine targeting multiple tumor-associated antigens, which is designed to treat various cancers, including non-small cell lung cancer and head and neck ...

A new mRNA vaccine could prevent pancreatic cancer from returning — potentially for the long haul. In a small clinical trial, some patients who received the vaccine remained cancer-free for more ...

A vaccine to prevent breast cancer is showing good results, and moving into the next stage of clinical trials. “This vaccine is designed eventually to prevent breast cancer,” said Amit Kumar ...

The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with pancreatic cancer this year. Of those, about 51,980 people (27,050 men and ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.

Early trials are meant to test whether or not a treatment is feasible — in this case, if an mRNA vaccine for pancreatic cancer could produce durable T cells. The findings suggest that it can.